Please assess the completion status of the following clinical trial:

Trial Title: Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer~* Age 18-60 years old~* Non-smoker~* must be able to fast 8 hours prior to exposure visits and for a further 4 hours during the exposure~Exclusion Criteria:~* Subjects must not be regularly taking multivitamins, vitamins C \& E, folate, medications, fish oil or aspirin, oral or inhaled steroids, for 4 weeks before and during the trial.~* Lipid abnormalities~* Asthma or respiratory disease~* Hypertension (Bp\> 140/90) or taking any blood pressure drug~* Known cardiac disease~* abnormal homocysteine or glucose levels

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- methyl donor (Type: EXPERIMENTAL): Methyl donor is made up of:~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
- placebo (Type: PLACEBO_COMPARATOR): placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.

Based on this trial design, predict the completion outcome and termination type (if applicable).